Current Liabilities decreased faster than Precigen Inc 's Cash & cash equivalent, this led to improvement in Precigen Inc 's Quick Ratio to 2.67, Quick Ratio remained below Precigen Inc average.

Within Major Pharmaceutical Preparations industry 247 other companies have achieved higher Quick Ratio than Precigen Inc in first quarter 2026. While Quick Ratio total ranking in the first quarter 2026 has deteriorated compared to the prior quarter from 976 to 986.

Explain Quick Ratio?
How much Cash & cash equivalents PGEN�s has?
What are PGEN�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

PGEN Quick Ratio	(Mar 31 2026) Q1	(Dec 31 2025) Q4	(Sep 30 2025) Q3	(Jun 30 2025) Q2	(Mar 31 2025) Q1
Y / Y Current Liabilities Change	-12.02 %	73.37 %	51.15 %	0.74 %	-16.64 %
Y / Y Cash & cash equivalent Change	-29.9 %	-0.05 %	323.09 %	205.86 %	79.28 %
Quick Ratio MRQ	2.67	2.62	3.78	2.58	3.35
PGEN's Total Ranking	# 986	# 976	# 668	# 800	# 719
Seq. Current Liabilities Change	-43.43 %	16.33 %	38.27 %	-3.31 %	11.47 %
Seq. Cash & cash equivalent Change	-42.52 %	-19.22 %	102.73 %	-25.53 %	-18.05 %

Quick Ratio first quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 248
Healthcare Sector	# 417
Overall Market	# 986

Quick Ratio Statistics
High	Average	Low
10.04	3.29	0.68
(Sep 30 2013)		(Sep 30 2022)

Financial Statements
Precigen Inc 's Current Liabilities	$ 21 Millions	Visit PGEN's Balance sheet
Precigen Inc 's Cash & cash equivalent	$ 56 Millions	Visit PGEN's Balance sheet
Source of PGEN's Sales		Visit PGEN's Sales by Geography

Cumulative Precigen Inc 's Quick Ratio

PGEN's Quick Ratio for the trailling 12 Months

PGEN Quick Ratio	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months	(Mar 31 2025) 12 Months
Y / Y Current Liabilities TTM Growth	26.66 %	23.3 %	4.97 %	-16.48 %	-22.24 %
Y / Y Cash & cash equivalent TTM Growth	48.02 %	88.11 %	130.48 %	32.67 %	-16.12 %
Quick Ratio TTM	2.95	3.08	3.56	2.96	2.52
Total Ranking TTM	# 3844	# 2942	# 2380	# 2893	# 2455
Seq. Current Liabilities TTM Growth	-2.47 %	15.67 %	12.07 %	0.19 %	-5.07 %
Seq. Cash & cash equivalent TTM Growth	-6.68 %	-0.01 %	34.71 %	17.77 %	18.59 %

Quick ratio ranking by company, industry and sector >> Back to PGEN Financial Strength Comparisons >> Go to Compare PGEN Quick Ratio to its Competitors

On the trailing twelve months basis In spite of the year on year decrease in PGEN's Current Liabilities to $21.10 millions, cumulative Quick Ratio to 2.95 above the company average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 429 other companies have achieved higher Quick Ratio than Precigen Inc . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2025 from 2942 to 3844.

Explain Quick Ratio?
How much Cash & cash equivalents PGEN�s has?
What are PGEN�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 430
Healthcare Sector	# 877
Within the Market	# 3844

trailing twelve months Quick Ratio Statistics
High	Average	Low
3.94	2.55	1.39
(Sep 30 2021)		(Jun 30 2023)

Companies with similar Quick Ratio in the quarter ending Mar 31 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Mar 31 2026 MRQ Cash & cash equivalent	Mar 31 2026 MRQ Current Liabilities
Ibio inc	7.32	$ 47.641 Millions	$ 6.504 Millions
Anaptysbio Inc	7.24	$ 286.455 Millions	$ 39.582 Millions
Avalo Therapeutics Inc	7.08	$ 82.140 Millions	$ 11.599 Millions
Alx Oncology Holdings Inc	6.95	$ 140.324 Millions	$ 20.178 Millions
Lyell Immunopharma Inc	6.88	$ 254.023 Millions	$ 36.947 Millions
Zymeworks Inc	6.85	$ 244.282 Millions	$ 35.649 Millions
Telomir Pharmaceuticals Inc	6.72	$ 5.561 Millions	$ 0.827 Millions
Biohaven Ltd	6.68	$ 347.817 Millions	$ 52.075 Millions
Silence Therapeutics Plc	6.63	$ 90.590 Millions	$ 13.668 Millions
Dermata Therapeutics Inc	6.60	$ 6.945 Millions	$ 1.053 Millions
Azitra Inc	6.49	$ 10.051 Millions	$ 1.550 Millions
Sionna Therapeutics Inc	6.48	$ 63.324 Millions	$ 9.776 Millions
Assembly Biosciences Inc	6.47	$ 226.601 Millions	$ 34.997 Millions
Renovorx Inc	6.44	$ 12.362 Millions	$ 1.920 Millions
Opus Genetics Inc	6.42	$ 59.959 Millions	$ 9.340 Millions
Amarin Corp Plcuk	6.40	$ 308.023 Millions	$ 48.153 Millions
Briacell Therapeutics Corp	6.35	$ 22.804 Millions	$ 3.590 Millions
Grace Therapeutics Inc	6.35	$ 16.977 Millions	$ 2.673 Millions
Annexon Inc	6.26	$ 225.025 Millions	$ 35.937 Millions
Tonix Pharmaceuticals Holding Corp	6.26	$ 185.470 Millions	$ 29.647 Millions
Arcturus Therapeutics Holdings Inc	6.15	$ 211.375 Millions	$ 34.369 Millions
Zentalis Pharmaceuticals Inc	6.01	$ 211.758 Millions	$ 35.236 Millions
Camp4 Therapeutics Corporation	5.97	$ 99.209 Millions	$ 16.624 Millions
Rocket Pharmaceuticals Inc	5.90	$ 144.379 Millions	$ 24.466 Millions
Bridgebio Oncology Therapeutics Inc	5.83	$ 252.275 Millions	$ 43.260 Millions
Actinium Pharmaceuticals Inc	5.73	$ 42.132 Millions	$ 7.349 Millions
Kura Oncology Inc	5.72	$ 580.823 Millions	$ 101.496 Millions
Catalyst Pharmaceuticals Inc	5.71	$ 755.859 Millions	$ 132.398 Millions
Cervomed Inc	5.69	$ 12.924 Millions	$ 2.272 Millions
Viking Therapeutics Inc	5.67	$ 602.964 Millions	$ 106.325 Millions

Date modified: 2026-09-26T07:06:18+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.